Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2009 5
2010 5
2011 8
2012 7
2013 4
2014 7
2015 7
2016 4
2017 9
2018 19
2019 9
2020 12
2021 9
2022 6
2023 6
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 38498661

96 results

Results by year

Filters applied: . Clear all
Page 1
Fosnetupitant.
[No authors listed] [No authors listed] 2024 Feb 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2024 Feb 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 38498661 Free Books & Documents. Review.
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G, Chilingirova N, Rizzi G, Caccia T, Stella V, Bernareggi A. Kurteva G, et al. Eur J Pharm Sci. 2019 Nov 1;139:105041. doi: 10.1016/j.ejps.2019.105041. Epub 2019 Aug 9. Eur J Pharm Sci. 2019. PMID: 31404621 Clinical Trial.
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, Fukui T, Minato K, Iwashima A, Takeda Y, Kubota K, Saeki T, Tamura T. Sugawara S, et al. Cancer. 2019 Nov 15;125(22):4076-4083. doi: 10.1002/cncr.32429. Epub 2019 Aug 5. Cancer. 2019. PMID: 31381152 Free PMC article. Clinical Trial.
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T. Kusagaya H, et al. Lung Cancer. 2015 Dec;90(3):410-6. doi: 10.1016/j.lungcan.2015.11.009. Epub 2015 Nov 7. Lung Cancer. 2015. PMID: 26791800 Clinical Trial.
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
Hata A, Shiraishi Y, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Hata A, et al. Oncol Ther. 2022 Jun;10(1):253-262. doi: 10.1007/s40487-022-00188-2. Epub 2022 Mar 4. Oncol Ther. 2022. PMID: 35246827 Free PMC article.
96 results